Geneos Therapeutics is a leading brand specializing in Personalized Therapeutic Cancer Vaccines (PTCV). They believe in the potential of their clinical trials to revolutionize cancer treatment. Unlike other vaccine platforms, Geneos includes virtually all of a patient's tumor-specific neoantigens, which arise from gene mutations in the tumor.

By respecting the fundamental importance of these neoantigens, Geneos aims to create an optimal therapeutic vaccine that allows the patient's immune system to fight their own cancer. The company's DNA-based vaccines have a high carrying capacity, ensuring that patients receive vaccines with all of their neoantigens. Geneos takes a radically simple approach by letting nature decide which neoantigens are relevant to unleashing the desired immune response.

Through extensive immunological studies, they have proven the value of this approach. Geneos' PTCVs offer the potential to treat all tumor types, even those with low mutational burden. The ongoing second-line clinical trial for hepatocellular carcinoma (HCC) has shown remarkable results, offering hope for patients with low mutational burden tumors.

Geneos' approach can turn cold tumors hot, and when combined with anti-PD1/PDL1 immunotherapies, it has shown synergistic effects for meaningful therapeutic benefit. With a focus on rapid vaccine manufacturing and delivery, Geneos strives to provide personalized vaccines to patients within six to eight weeks of obtaining a tumor biopsy. Their goal is to further improve manufacturing speed and achieve a turnaround time of three to four weeks upon commercialization.

Using the patient's own immune system, Geneos' PTCVs induce CD4 and CD8 T cells against the tumor. Their proprietary electroporation (EP) device optimizes vaccine effectiveness and ensures an effective T cell response to neoantigens. Geneos' PTCVs offer a promising foundational approach for treating cancers that are not responsive to other immunotherapies